Danaher (DHR) Receives New Coverage from Analysts at Barclays

Barclays assumed coverage on shares of Danaher (NYSE:DHR) in a research report sent to investors on Thursday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $110.00 price target on the conglomerate’s stock.

A number of other equities research analysts also recently issued reports on DHR. Stifel Nicolaus increased their price target on Danaher from $110.00 to $115.00 and gave the stock a buy rating in a research report on Wednesday, January 31st. Credit Suisse Group increased their price target on Danaher from $99.00 to $105.00 and gave the stock an outperform rating in a research report on Wednesday, January 31st. Royal Bank of Canada reissued a hold rating and set a $98.00 price target on shares of Danaher in a research report on Wednesday, January 31st. Morgan Stanley increased their price target on Danaher from $103.00 to $110.00 and gave the stock an overweight rating in a research report on Wednesday, January 31st. Finally, Argus increased their price target on Danaher from $100.00 to $115.00 and gave the stock a buy rating in a research report on Thursday, February 1st. One analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Danaher currently has an average rating of Buy and a consensus price target of $100.68.

Danaher (DHR) opened at $97.54 on Thursday. The company has a market capitalization of $67,946.36, a P/E ratio of 27.63, a PEG ratio of 2.05 and a beta of 1.04. Danaher has a 12-month low of $78.97 and a 12-month high of $104.82. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.43 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.03. The business had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.05 earnings per share. sell-side analysts expect that Danaher will post 4.37 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, January 26th. Shareholders of record on Friday, December 29th were paid a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a yield of 0.57%. The ex-dividend date was Thursday, December 28th. Danaher’s payout ratio is presently 15.86%.

In other Danaher news, CFO Daniel L. Comas sold 62,989 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the completion of the sale, the chief financial officer now directly owns 227,805 shares in the company, valued at $23,226,997.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP William K. Daniel sold 131,066 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $102.05, for a total value of $13,375,285.30. Following the sale, the executive vice president now owns 270,523 shares of the company’s stock, valued at $27,606,872.15. The disclosure for this sale can be found here. Insiders have sold 237,043 shares of company stock valued at $24,194,886 over the last 90 days. Corporate insiders own 12.20% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sawtooth Solutions LLC bought a new position in shares of Danaher in the 4th quarter valued at $308,000. HM Payson & Co. lifted its stake in shares of Danaher by 2.6% in the 4th quarter. HM Payson & Co. now owns 213,314 shares of the conglomerate’s stock valued at $19,800,000 after acquiring an additional 5,348 shares during the last quarter. WealthPLAN Partners LLC bought a new position in shares of Danaher in the 4th quarter valued at $209,000. Fieldpoint Private Securities LLC lifted its stake in shares of Danaher by 44.7% in the 4th quarter. Fieldpoint Private Securities LLC now owns 8,160 shares of the conglomerate’s stock valued at $757,000 after acquiring an additional 2,520 shares during the last quarter. Finally, Hunter Associates Investment Management LLC bought a new position in shares of Danaher in the 4th quarter valued at $205,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://ledgergazette.com/2018/02/18/danaher-dhr-receives-new-coverage-from-analysts-at-barclays.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply